Oncopeptides AB (publ) (LON:0RN4)

-37.64% (1Y)

Market Cap	30.39M
Revenue (ttm)	2.28M
Net Income (ttm)	-20.54M
Shares Out	n/a
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	980
Average Volume	1,180
Open	1.920
Previous Close	1.924
Day's Range	1.854 - 1.854
52-Week Range	0.108 - 0.565
Beta	n/a
RSI	46.36
Earnings Date	May 15, 2025

About Oncopeptides AB

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company also engages in the research for small popypeptide based killer engages for the treatment of RRMM and hematological or solid tumors; and other peptide-drug conjugates for ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2000
• Employees: 80
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RN4

Financial Performance

In 2024, Oncopeptides AB's revenue was 31.65 million, a decrease of -10.14% compared to the previous year's 35.22 million. Losses were -284.61 million, 14.2% more than in 2023.

Financial numbers in SEK